Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CVM Updates

CVM Updates Home
          Animal & Veterinary
          News & Events
          CVM Updates
          FDA Announces FY 2024 Animal Drug User Fee Rates for ADUFA and AGDUFACVM Updates FDA Announces FY 2024 Animal Drug User Fee Rates for ADUFA and AGDUFA
  
  	
    Share
    Post
    Linkedin

    Email
    PrintOctober 20, 2023

The U.S. Food and Drug Administration has announced in the Federal Register the fiscal year (FY) 2024 fee rates and payment procedures for animal drugs subject to user fees under the Animal Drug and Animal Generic Drug User Fee Amendments of 2023.

The Animal Drug User Fee Act (ADUFA), originally signed into law in 2003 and reauthorized in 2008, 2013, 2018 and 2023, authorizes the FDA to collect fees for certain animal drug applications and supplemental applications, products, establishments, and sponsors of animal drug applications and/or investigational animal drug submissions. These resources supplement funding provided by Congressional budget authority to enhance the performance of the drug review process ensuring that new animal drug products are safe and effective for animals, and that food derived from treated animals will be safe for consumption. ADUFA V reauthorizes the FDA to collect user fees through FY 2028.

The Animal Generic Drug User Fee Act (AGDUFA), originally signed into law in 2008 and reauthorized in 2013, 2018 and 2023, was designed to supplement the Congressional budget authority to enhance the performance of the generic new animal drug review process, which enables the FDA to ensure that generic new animal drug products are safe and effective. AGDUFA IV reauthorizes the FDA to collect user fees for certain abbreviated applications for generic new animal drugs, generic investigational new animal drug files, generic new animal drug products, and from certain sponsors of abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs. The user fees for sponsors are prorated based on the number of approved abbreviated applications the sponsor currently holds.  AGDUFA IV reauthorizes the FDA to collect user fees through FY 2028.

In the period since Congress first passed ADUFA in 2003 until September 30, 2023, the FDA has approved 524 new animal drugs -- both original approvals and major enhancements to these approvals (e.g., new indications, new species). In the period since AGDUFA was passed in 2008 until September 30, 2023, the FDA has approved 354 generic new animal drugs.

The tables below reflect the ADUFA V and AGDUFA IV fee rates for FY 2024.

ADUFA V FY 2024 Fees

Animal Drug User Fee Category
			Fee Rate for FY 2024Animal Drug Application Fees:
			Animal Drug Application
				Supplemental Animal Drug Application requiring safety or effectiveness data and Animal Drug Application subject to criteria in 21 U.S.C. 360b(d)(4))(50% of application fee)
			$683,673
			$341,837Product Fee
			$12,459Establishment Fee
			$174,200Sponsor Fee
			$153,305

AGDUFA IV FY 2024 Fees

Generic New Animal Drug User Fee Category
			Fee Rate for FY 2024Abbreviated Application for a Generic New Animal Drug (except those subject to criteria in 21 U.S.C. 360b(d)(4))
			$126,582Abbreviated Application for a Generic New Animal Drug subject to criteria in 21 U.S.C. 360b(d)(4) (50% of application fee)
			$63,291Generic Investigational New Animal Drug File Fee (JINAD)
			$50,000Product Fee
			$16,393Sponsor Fee
			100% (holds > 6 approved abbreviated applications)
			75% (holds 2-6 approved abbreviated applications)
			50% (holds 0-1 approved abbreviated applications)
			$258,331 
			$193,748 
			$129,166

In addition to announcing the ADUFA and AGDUFA user fee rates for FY 2024 and explaining how such rates were calculated, the Federal Register notices also provide details on how to submit payment of these fees to the FDA. The application fee rates are effective for applications received by the FDA’s Center for Veterinary Medicine from October 1, 2023, until September 30, 2024. The FDA will issue invoices for FY 2024 product, establishment, and sponsor fees by December 31, 2023, and payment will be due by January 31, 2024. The FDA will not accept an application for filing unless the FDA has received payment for all fees due from the sponsor.

For additional information regarding the financials and performance of ADUFA and AGDUFA, we have included a link for the FY 2022 Financial and Performance Reports below.

For more information, contact Lisa Kable at Lisa.Kable@fda.hhs.gov. Please send general questions concerning ADUFA to cvmadufa@fda.hhs.gov and questions concerning AGDUFA to cvmagdufa@fda.hhs.gov.

Additional Information:

Federal Register Notice; Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2024
	Federal Register Notice; Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2024
	ADUFA Financial Reports
	ADUFA Performance Reports
	AGDUFA Financial Reports
	AGDUFA Performance Reports**Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.**

                                                                                  Content current as of:
      10/20/2023CVM Updates
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop